First, identification of patients with high levels of active enzyme may support the discovery of a patient sub-population who might benefit most from the use of an inhibitor or an enzyme-targeted anti-tumor agent, such as the recently described anti-DR5/FAP bispecific antibody50. Here, FAP is linked to neoplasm.